Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

por Gimsing, P, Hjertner, Ø, Abildgaard, N, Andersen, N F, Dahl, T G, Gregersen, H, Klausen, T W, Mellqvist, U-H, Linder, O, Lindås, R, Tøffner Clausen, N, Lenhoff, S
Publicado 2015

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESUL...

por Groen, K., Seefat, M. R., van der Holt, B., Schjesvold, F. H., Stege, C. A., Levin, M.-D., Hansson, M., Leys, R. B., Regelink, J., Waage, A., Szatkowski, D., Axelsson, P., Do, T. H., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C., Mellqvist, U.-H., van de Donk, N. W., Sonneveld, P., Klostergaard, A., Vangsted, A. J., Abdilgaard, N., Zweegman, S.
Publicado 2022